NCT00778414View on ClinicalTrials.gov

Bioequivalence Study of Amoxicillin-Clavulanic Acid 600 mg - 42.9 mg/ 5 mL Oral Suspension Under Fasting Conditions

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

July 31, 2006

Study Completion Date

September 30, 2006

Conditions

Healthy

Interventions

DRUG

Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension

Trial Locations (1)

G1V2K8

Anapharm, Québec

All Listed Sponsors

lead

Ranbaxy Laboratories Limited

INDUSTRY

NCT00778414 - Bioequivalence Study of Amoxicillin-Clavulanic Acid 600 mg - 42.9 mg/ 5 mL Oral Suspension Under Fasting Conditions | Biotech Hunter | Biotech Hunter